Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 3/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505777 | 0.80 | SRC (0.35) | APPLMNAKMT2A | |
| SCHEMBL3568407 | 0.76 | LTB4R (0.33) | APPNR3C2MIFGPR119 | |
| SCHEMBL24216867 | 0.71 | MAPT (0.49) | LMNAGPR119 | |
| SCHEMBL2437569 | 0.70 | TDP1 (0.44) | APPLMNAKMT2A | |
| SCHEMBL21902944 | 0.69 | APP (0.41) | APPLMNAKMT2AABCB1EDNRA | |
| SCHEMBL24089543 | 0.69 | APP (0.41) | APPLMNAKMT2AABCB1EDNRA | |
| SCHEMBL3503733 | 0.69 | APP (0.36) | APPLMNA | |
| SCHEMBL1704771 | 0.68 | ALDH1A1 (0.37) | LMNA | |
| SCHEMBL3568409 | 0.68 | LTB4R (0.34) | APP | |
| SCHEMBL4192407 | 0.66 | NPSR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7772238-B2 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772238-B2 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
| WO-2006115835-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | BRDT, HDAC5, BRPF3 | APP 2453/4885LMNA 3783/4885KMT2A 71/4885 |
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | APP 2353/4885LMNA 3991/4885KMT2A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.